New pill shows promise for anemia in kids with kidney disease
NCT ID NCT05682326
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a drug called daprodustat in children aged 3 months to under 18 years who have anemia due to chronic kidney disease. The goal was to see how the drug moves through the body and if it is safe. Only 4 children took part, and they received the drug for up to 52 weeks. The study looked at side effects and changes in red blood cell levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
daprodustat
What this could lead to
If successful, this could provide a new treatment option for anemia in children with chronic kidney disease, potentially reducing the need for injections.
What could go wrong
This was a very small study with only 4 participants, so results may not apply to all children. The drug also carries risks like blood clots and high blood pressure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Aichi, 466-8650, Japan
-
GSK Investigational Site
Saitama, 330-8777, Japan
-
GSK Investigational Site
Tokyo, 162-8666, Japan
-
GSK Investigational Site
Yangsan, 50612, South Korea